Safety and immunogenicity of a potential checkpoint blockade vaccine for canine melanoma

Kurupati, Raj K.; Zhou, Xiangyang; Xiang, Zhiquan; Ertl, Hildegund C.J.

doi:10.1007/s00262-018-2201-5

Cited by 8 publications

(3 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Malignant melanoma is among the most common cancers in dogs (4,5). The most diffuse and fatal subtype is oral malignant melanoma (OMM), which accounts for 30-40% of all canine oral malignancies (6, 7) and 20.3 cases per 100,000 dogs per year (4,5). OMM is characterized by local invasiveness and high metastatic propensity (6,8,9).…”

Section: Canine Oral Malignant Melanomamentioning

confidence: 99%

Canine Melanoma Immunology and Immunotherapy: Relevance of Translational Research

et al. 2022

View full text Add to dashboard Cite

In veterinary oncology, canine melanoma is still a fatal disease for which innovative and long-lasting curative treatments are urgently required. Considering the similarities between canine and human melanoma and the clinical revolution that immunotherapy has instigated in the treatment of human melanoma patients, special attention must be paid to advancements in tumor immunology research in the veterinary field. Herein, we aim to discuss the most relevant knowledge on the immune landscape of canine melanoma and the most promising immunotherapeutic approaches under investigation. Particular attention will be dedicated to anti-cancer vaccination, and, especially, to the encouraging clinical results that we have obtained with DNA vaccines directed against chondroitin sulfate proteoglycan 4 (CSPG4), which is an appealing tumor-associated antigen with a key oncogenic role in both canine and human melanoma. In parallel with advances in therapeutic options, progress in the identification of easily accessible biomarkers to improve the diagnosis and the prognosis of melanoma should be sought, with circulating small extracellular vesicles emerging as strategically relevant players. Translational advances in melanoma management, whether achieved in the human or veterinary fields, may drive improvements with mutual clinical benefits for both human and canine patients; this is where the strength of comparative oncology lies.

show abstract

Section: Canine Oral Malignant Melanomamentioning

confidence: 99%

Canine Melanoma Immunology and Immunotherapy: Relevance of Translational Research

et al. 2022

View full text Add to dashboard Cite

show abstract

“…All dogs responded with increased frequencies of mFAP-specific activated CD8+ and CD4+ T cells. Further testing of this checkpoint blockade vaccine combination in dogs with melanoma is necessary (Kurupati et al 2018). The rapidly expanding field of cancer immunology and immunotherapeutics means that rational targeting of MM in both humans and dogs should enhance treatment outcomes in veterinary and human patients.…”

Section: Melanomamentioning

confidence: 99%

Skin and Subcutaneous Tumors

Wouters¹,

Nimwegen²,

Ryan³

et al. 2022

Veterinary Surgical Oncology

View full text Add to dashboard Cite

“…However, experimental results with tumor vaccines have shown limited benefits, mainly related to nonspecific activation of the immune system and, in cases of solid tumors, there are reports of an exacerbated inflammatory reaction at the application site (72) . For this reason, new methodologies have been evaluated, such as the investigation of a checkpoint inhibitor vaccine for the treatment of canine melanoma (76) , and the development of a canine telomerase DNA vaccine (77,78) . These products were able to generate specific immune response, mainly with a significant increase in T cells.…”

Section: Applications and Perspectives Of Immunotherapy In Oncologymentioning

confidence: 99%

Elucidating tumor immunosurveillance and immunoediting: a comprehensive review

et al. 2021

View full text Add to dashboard Cite

The action of the immune system against neoplastic diseases has become one of the main sources of research. The biological pathways of this system are known to contribute in limiting the progression and elimination of the tumor, and are delineated by concepts and mechanisms of immunosurveillance and immunoediting. Immunosurveillance is considered the process by which the immune system recognizes and inhibits the neoplastic process. The concept of immunoediting arises in the sense that immune system is able to shape the antigenic profile of the tumor due to selective pressure, based on the stages of tumor elimination, balance and evasion. The immune response occurs against tumor antigens and changes in the tumor microenvironment, involving different components of the innate immune system, such as T cells, natural Killer cells, B lymphocytes and macrophages. In this sense, knowing these concepts and understanding their respective mechanisms becomes essential in the investigation of new strategies for cancer prevention and cure. Thus, this review presents historical aspects and definitions of immunosurveillance and tumor immunoediting, with emphasis on its importance and applicability, such as on the different methods used in immunotherapy.

show abstract

Safety and immunogenicity of a potential checkpoint blockade vaccine for canine melanoma

Cited by 8 publications

References 52 publications

Canine Melanoma Immunology and Immunotherapy: Relevance of Translational Research

Canine Melanoma Immunology and Immunotherapy: Relevance of Translational Research

Skin and Subcutaneous Tumors

Elucidating tumor immunosurveillance and immunoediting: a comprehensive review

Contact Info

Product

Resources

About